Chapter 15. Pharmacogenomics of Dasatinib (Sprycel™)

  1. Rongshi Li and
  2. Jeffrey A. Stafford
  1. Fei Huang and
  2. Edwin A. Clark

Published Online: 28 SEP 2009

DOI: 10.1002/9780470524961.ch15

Kinase Inhibitor Drugs

Kinase Inhibitor Drugs

How to Cite

Huang, F. and Clark, E. A. (2009) Pharmacogenomics of Dasatinib (Sprycel™), in Kinase Inhibitor Drugs (eds R. Li and J. A. Stafford), John Wiley & Sons, Inc., Hoboken, NJ, USA. doi: 10.1002/9780470524961.ch15

Editor Information

  1. Takeda San Diego, Inc., San Diego, CA 92121, USA

Author Information

  1. Oncology Clinical Biomarkers, Discovery Medicine & Clinical Pharmacology, Bristol-Myers Squibb Company, Princeton, NJ 08540, USA

Publication History

  1. Published Online: 28 SEP 2009
  2. Published Print: 2 OCT 2009

Book Series:

  1. Wiley Series in Drug Discovery and Development

Book Series Editors:

  1. Binghe Wang

ISBN Information

Print ISBN: 9780470278291

Online ISBN: 9780470524961

SEARCH

Options for accessing this content:

  • If you have access to this content through a society membership, please first log in to your society website.
  • Login via other institutional login options http://onlinelibrary.wiley.com/login-options.
  • You can purchase online access to this Chapter for a 24-hour period (price varies by title)
    • If you already have a Wiley Online Library or Wiley InterScience user account: login above and proceed to purchase the article.
    • New Users: Please register, then proceed to purchase the article.

Login via OpenAthens

or

Search for your institution's name below to login via Shibboleth.

Please register to:

  • Save publications, articles and searches
  • Get email alerts
  • Get all the benefits mentioned below!

Register now >